Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Pradaxa

Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Pradaxa

Notification of an important new warning with treatment of patients with anti phospholipid syndrome (APS) and the use Pradaxa: Increased risk of thrombo-embolic events

2019 Aug

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance